Cargando…
Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update
Lung cancer (LC) is the leading cause of cancer-related deaths, responsible for approximately 18.4% of all cancer mortalities in both sexes combined. The use of systemic therapeutics remains one of the primary treatments for LC. However, the therapeutic efficacy of these agents is limited due to the...
Autores principales: | Abdulbaqi, Ibrahim M., Assi, Reem Abou, Yaghmur, Anan, Darwis, Yusrida, Mohtar, Noratiqah, Parumasivam, Thaigarajan, Saqallah, Fadi G., Wahab, Habibah A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400724/ https://www.ncbi.nlm.nih.gov/pubmed/34451824 http://dx.doi.org/10.3390/ph14080725 |
Ejemplares similares
-
Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview
por: A. Razak, S. Aishah, et al.
Publicado: (2021) -
Ethosomal nanocarriers: the impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials
por: Abdulbaqi, Ibrahim M, et al.
Publicado: (2016) -
Lyophilized Hybrid Nanostructured Lipid Carriers to Enhance the Cellular Uptake of Verapamil: Statistical Optimization and In Vitro Evaluation
por: Khan, Arshad Ali, et al.
Publicado: (2018) -
Eurycoma longifolia: an overview on the pharmacological properties for the treatment of common cancer
por: Jothi, Shankar, et al.
Publicado: (2023) -
Solid Lipid Nanoparticles of Atovaquone Based on 2(4) Full-Factorial Design
por: Mohtar, Noratiqah, et al.
Publicado: (2015)